Page 7 - Cancer Annual Congress News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study

OP-1250 in combination with palbociclib was well-tolerated in patients with ER+/HER2- metastatic breast cancer, with no dose-limiting toxicities, and no observed drug-drug interaction Overall. | May 11, 2023

San franciscoUnited statesUnited kingdomIgnacio guerrero rosSeanp bohenShane kovacsOlema pharmaceuticals incBreast cancer annual congressSecurities exchangeExchange commissionCancer annual congressOral complete estrogen receptor antagonistChief executive officerRecommended phaseSecurities actSecurities exchange act

OLEMA PHARMACEUTICALS, INC : Other Events (form 8-K)

Item 8.01Other Events. On May 11, 2023, Olema Pharmaceuticals, Inc. announced interim results from an ongoing Phase 1b/2 clinical study of OP-1250, the Company s complete estrogen receptor . | May 11, 2023

Securities exchangeBreast cancer annual congressOlema pharmaceuticals incExchange commissionCancer annual congressOral complete estrogen receptor antagonistRecommended phaseSecurities actSecurities exchange actAnnual reportCurrent reportExchange actPage interactive data fileEdgar onlineOlema pharmaceuticalsNc stock exchange

Olema (OLMA) Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study

Olema (OLMA) Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Seanp bohenOlema pharmaceuticals incBreast cancer annual congressWall streetCancer annual congressOral complete estrogen receptor antagonistChief executive officerRecommended phase

Post-Hoc Analysis Shows Olaparib Maintains PFS Benefit in gBRCA+ HER2– Metastatic Breast Cancer, Irrespective of ER Expression

Olaparib provided consistent clinical benefit in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer, irrespective of estrogen receptor expression level.

British columbiaUnited kingdomOlaparib lynparzaKarena gelmonBreast cancer annual congressUniversity of british columbiaCancer annualCancer annual congressEsmo breast cancer virtual meetingBreast cancer

Toxicity Profile With Trastuzumab Deruxtecan Proves Consistent, Manageable in HER2-Low Metastatic Breast Cancer

Treatment with trastuzumab deruxtecan resulted in lower exposure-adjusted incidence rates per patient-year of treatment-emergent adverse effects compared with treatment of physician’s choice in patients with HER2-low unresectable and/or metastatic breast cancer, according to safety analysis from the phase 3 DESTINY-Breast04 trial.

United statesSan franciscoPionyr immunotherapeuticsDaiichi sankyoTaiho oncology incCancer infusion servicesBreast cancer annual congressNovartis pharmaceuticals corporationDaiichi sankyo incSermonix pharmaceuticals incHelen diller family comprehensive cancer centerVeru incRoche ag genentech incDepartment of medicineAstellas pharma incMerck co inc